CEU CMC Vellore
Professor of Biostatistics · Christian Medical College Vellore
CEU CMC Vellore, listed as Professor of Biostatistics, hosts the 2023 and 2025 Clinical Trials Course at Christian Medical College Vellore.
- lectures
- 17
- series
- 2
- hours
- 18
Start here
Series and courses
Clinical Trials Course - 2023
Open the course
- 1TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- 2TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- 3SYSTEMATIC REVIEW _ DR THAMBU DAVID
- 4STUDY DESIGNS _ DR THAMBU DAVID
Show 10 moreShow fewer
- 5SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- 6PHASE I AND PHASE II DESIGNS _ DR MAHESH IYER
- 7OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- 8INTERIM ANALYSIS IN A CLINICAL TRIAL _ DR SHRIKANT I BANGDIWALA
- 9DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- 10CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- 11CONFIDENCE INTERVALS _ DR. L. JEYASEELAN
- 12CONDITION POWER IN INTERIM ANALYSES OF A CLINICAL TRIAL _ DR. L. JEYASEELAN
- 13COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- 14COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART I _ DR. SHRIKANT I. BANGDIWALA
In these lectures
- Critical appraisal requires a skeptical mindset to protect patient safety.CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- Systematic and historical controls introduce severe personal and selective biases into clinical trials.OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- Clinical outcomes must be chosen based on clinical relevance rather than statistical convenience.DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
Draws on
People cited in the lectures, at the moment of the citation.
- John IoannidisProfessor of medicine at Stanford University, author of 'Why Most Published Research Findings Are False'
- Dr. JayLecturer or colleague cited regarding statistical principles
- Dr. MaheshLecturer or colleague cited regarding safety outcomes
- Philip BermanVaccine inventor cited regarding the interpretation of the VaxGen trial results.
- Dr. John EikelboomPrincipal investigator for a study determining non-inferiority margins involving Factor XI and Rivaroxaban
- Dr. JayaseelanLecturer cited for presenting proportions and event rates in a previous session.
About
CEU CMC Vellore, listed as Professor of Biostatistics, hosts the 2023 and 2025 Clinical Trials Course at Christian Medical College Vellore. Sessions on Phase III trial methods cover sample size, Pocock and O'Brien-Fleming boundaries, conditional power and a CONSORT appraisal of an asthma trial.
Taught with
Same subject, Medicine & Health
Connections
21Their places, courses, books and lectures.
Institution1
Concept1
Lectures17
- CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- STUDY DESIGNS _ DR THAMBU DAVID
- SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
Show 11 moreShow fewer
- TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- PHASE I AND PHASE II DESIGNS _ DR MAHESH IYER
- CONDITION POWER IN INTERIM ANALYSES OF A CLINICAL TRIAL _ DR. L. JEYASEELAN
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART I _ DR. SHRIKANT I. BANGDIWALA
- Day 2 (II) - Design considerations - Necessary sample size_ Prof. L.Jeyaseelan
- Day 3 (III)-Case studies for early stopping: Condition Power in Interim Analyses _Prof. L.Jeyaseelan
- INTERIM ANALYSIS IN A CLINICAL TRIAL _ DR SHRIKANT I BANGDIWALA
- Day 3 (IV) Crossover trials design and analysis_ Dr.Visalakshi
- CONFIDENCE INTERVALS _ DR. L. JEYASEELAN
- SYSTEMATIC REVIEW _ DR THAMBU DAVID


